From: Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence
 | Muscle damage (N = 16) | Atrophy (N = 17) | Both (N = 6) |
---|---|---|---|
WIE | |||
 V2 – V0 | −6.83 (7.13) (− 10.6; – 3.0)* | −6.17 (5.30) (− 8.9; – 3.4)* | −10.58 (8.54) (− 19.5; – 1.6)* |
 V3 – V0 | −9.25 (9.67) (− 14.4; – 4.1)* | −8.55 (7.12) (− 12.2; – 4.9)* | −19.79 (15.23) (− 35.8; – 3.8)* |
 V4 – V0 | − 9.29 (10.08) (−14.7; – 3.9)* | −8.09 (5.83) (− 11.1; – 5.1)* | −23.33 (13.14) (− 19.5; – 1.6)* |
Wexner score | |||
 V2 – V0 | −13.44 (5.23) (− 16.2; – 10.7)* | −16.82 (3.81) (− 18.8; – 14.9)* | − 15.33 (3.50) (− 19.0; – 11.7)* |
 V3 – V0 | −14.25 (4.99) (− 16.2; – 10.7)* | −18.29 (2.39) (− 19.5; – 17.1)* | −14.50 (4.97) (− 19.7; – 9.3)* |
 V4 – V0 | − 14.94 (4.42) (− 16.9; – 11.6)* | −17.71 (1.99) (− 18.7; – 16.7)* | −17.67 (3.14) (− 21.0; – 14.4)* |
VAS | |||
 V2 – V0 | −2.79 (2.11) (− 3.9; – 1.7)* | −3.07 (2.40) (− 4.4; – 1.7)* | −2.37 (1.72) (− 4.2; – 0.6)* |
 V3 – V0 | −3.65 (− 2.60) (− 5.0; – 2.3)* | −4.23 (2.41) (− 5.6; – 2.8)* | −4.10 (1.47) (− 5.9; – 2.3)* |
 V4 – V0 | −3.71 (2.84) (− 5.2; – 2.2)* | − 4.45 (2.35) (− 5.8; – 3.1)* | −5.89 (2.45) (− 9.8; – 2.0)* |